CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

  • Identifying Heterogeneity Within Rare Cell Populations By Pairing Single-Cell RNA-Seq With Cell Sorting

    Studying biology at a single-cell level can provide crucial insights into how individual cells contribute to human biology and disease. Here we demonstrate that the resolution of single-cell RNA sequencing (RNA-Seq) can be greatly enhanced by adding a cell sorting step prior to RNA-Seq analysis.

  • Registry And Natural History Studies: Vital, Contrasting Roles In Rare Disease Clinical Research

    Both registry studies and natural history studies play important roles in rare disease research. Understanding the differences between the two types of studies and how they can be used to inform clinical development can help sponsors plan for success.

  • Drug Substance Management With Single Use vs. Stainless Steel

    Fast freeze rates, safe storage and proper shipping of bulk drug substances are imperative. This case study compares the advantages and disadvantages of single-use systems and cryovessels.

  • The Science Of Cell Therapy Thawing

    This guide summarizes the science of thawing following conventional, slow freezing methods. We address how cell thawing has historically developed into the techniques used today, along with the physical and biological implications of key metrics and components, such as warming rate and ice structure. Also included are reviews of key studies from scientific literature and a consideration of the interactions between cooling and warming rates, as applicable to cell and gene therapies.

  • Switch To A Nitrogen-Free Cryopreservation System

    This study focuses on the running costs and carbon emissions associated with cryopreservation equipment, comparing a liquid nitrogen (LN2)-free controlled-rate freezer with a typical liquid nitrogen-based system. The environmental implications of using liquid nitrogen for cell freezing are explored along with carbon emissions during the manufacture, transportation, and operation of LN2-free controlled-rate freezers.

  • Tumor-Agnostic Treatments: A Game Changer For Rare Oncology Trials

    As our understanding of the molecular characteristics of tumors has improved, there has been a tremendous leap forward — not only in targeted therapies but also in the development of tumor-or tissue-agnostic treatments. Now, with precision or personalized medicine, treatments can be targeted to a subgroup of patients rather than relying on a one-drug-fits-all model. In this blog post, we explore the changing rare oncology landscape and novel approaches to rare cancer trials.

  • The Future Of MilliporeSigma’s Gene Therapy CDMO Through The Lens Of History

    On the road to becoming a global industry leader in cell and gene therapy, our viral vector manufacturing organization has undergone a major transformation over the last two decades. Marc Gaal, Director of Program Management at MilliporeSigma, details the history of the business as well as some of the milestones achieved since its inception.

  • Developing A Continuous Large-Scale Perfusion Cell Culture Process

    The key benefits of perfusion processes are compact process design, flexibility, increased productivity, increased yield, and consistent product quality. 

  • A Model To Increase Yield In mAb Cell Culture Perfusion At Large Scale

    As process intensification is adopted into large scale manufacturing, the responsibility of scale-down models to accurately represent the expanded operating space quickly follows. 

  • Effective Downstream Purification: Clinical-Stage Retrovirus-Like Particles

    Purification of enveloped viruses and virus-like particles is challenging due to their size and complexity. This study demonstrates resin screening, process development, and scale-up purification approaches. 

erin-header4

CELL AND GENE LIVE

21_01_CG_InnovationCellManufaturing_300x200_OD

 

In this on-demand webinar Cell & Gene Chief Editor Erin Harris talks with Dr. Mark Gilbert, SVP of R&D at Acepodia, Thomas Lequertier, Head of Cell Therapy Manufacturing Unit at Celyad Oncology, and Luděk Sojka, Ph.D., Chief Technology Officer at SOTIO, about the innovations in manufacturing that can reduce both costs and risks.

Cell & Gene Live On-Demand

CELL AND GENE CONTENT COLLECTIONS

21_01_CG_AdvancementsCellTherapy_Ebook_300x200

 

Even though cell therapy and gene therapy are overlapping fields of biomedical research, there are differences between them that are germane to each. Cell therapy has challenges and risks all its own. For your reference, here are some of the latest articles that will help you better understand the benefits, risks, costs, and more associated with cell therapy.

More Content Collections